reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
===== MeSH D08.811.913.696 – phosphotransferases (EC 2.7) ===== MeSH D08.811.913.696.175 – diphosphotransferases MeSH D08.811.913.696.175.300 – gtp pyrophosphokinase MeSH D08.811.913.696.175.650 – ribose-phosphate pyrophosphokinase MeSH D08.811.913.696.175.825 – thiamin pyrophosphokinase MeSH D08.811.913.696.310 – myosin type iii MeSH D08.811.913.696.445 – nucleotidyltransferases MeSH D08.811.913.696.445.035 – n-acylneuraminate cytidylyltransferase MeSH D08.811.913.696.445.184 – choline-phosphate cytidylyltransferase MeSH D08.811.913.696.445.308 – dna nucleotidyltransferases MeSH D08.811.913.696.445.308.300 – dna-directed dna polymerase MeSH D08.811.913.696.445.308.300.112 – dna polymerase beta MeSH D08.811.913.696.445.308.300.225 – dna polymerase i MeSH D08.811.913.696.445.308.300.230 – dna polymerase ii MeSH D08.811.913.696.445.308.300.235 – dna polymerase iii MeSH D08.811.913.696.445.308.300.750 – RNA-directed dna polymerase MeSH D08.811.913.696.445.308.300.750.375 – hiv-1 reverse transcriptase MeSH D08.811.913.696.445.308.300.750.750 – telomerase MeSH D08.811.913.696.445.308.300.875 – taq polymerase MeSH D08.811.913.696.445.308.325 – dna nucleotidylexotransferase MeSH D08.811.913.696.445.400 – glucose-1-phosphate adenylyltransferase MeSH D08.811.913.696.445.600 – nicotinamide-nucleotide adenylyltransferase MeSH D08.811.913.696.445.625 – 2',5'-oligoadenylate synthetase MeSH D08.811.913.696.445.650 – polynucleotide adenylyltransferase MeSH D08.811.913.696.445.692 – rec a recombinases MeSH D08.811.913.696.445.735 – rna nucleotidyltransferases MeSH D08.811.913.696.445.735.265 – dna, catalytic MeSH D08.811.913.696.445.735.270 – dna-directed rna polymerases MeSH D08.811.913.696.445.735.270.375 – dna primase MeSH D08.811.913.696.445.735.270.750 – rna polymerase i MeSH D08.811.913.696.445.735.270.762 – rna polymerase ii MeSH D08.811.913.696.445.735.270.775 – rna polymerase iii MeSH D08.811.913.696.445.735.270.887 – rna polymerase sigma 54 MeSH D08.811.913.696.445.735.532 – polyribonucleotide nucleotidyltransferase MeSH D08.811.913.696.445.735.630 – q beta replicase MeSH D08.811.913.696.445.735.720 – rna helicases MeSH D08.811.913.696.445.735.720.500 – eukaryotic initiation factor-4a MeSH D08.811.913.696.445.735.780 – rna replicase MeSH D08.811.913.696.445.735.917 – rna, ribosomal, self-splicing MeSH D08.811.913.696.445.800 – sulfate adenylyltransferase MeSH D08.811.913.696.445.825 – transposases MeSH D08.811.913.696.445.825.500 – hiv integrase MeSH D08.811.913.696.445.837 – transposon resolvases MeSH D08.811.913.696.445.850 – UDP-glucose—hexose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.875 – UTP—glucose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.900 – UTP—hexose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.950 – vdj recombinases MeSH D08.811.913.696.620 – phosphotransferases (alcohol group acceptor) MeSH D08.811.913.696.620.010 – adenosine kinase MeSH D08.811.913.696.620.155 – choline kinase MeSH D08.811.913.696.620.175 – deoxycytidine kinase MeSH D08.811.913.696.620.200 – diacylglycerol kinase MeSH D08.811.913.696.620.225 – fructokinases MeSH D08.811.913.696.620.225.850 – phosphofructokinases MeSH D08.811.913.696.620.225.850.500 – phosphofructokinase-1 MeSH D08.811.913.696.620.225.850.500.249 – phosphofructokinase-1, liver type MeSH D08.811.913.696.620.225.850.500.500 – phosphofructokinase-1, muscle type MeSH D08.811.913.696.620.225.850.500.750 – phosphofructokinase-1, type c MeSH D08.811.913.696.620.225.850.750 – phosphofructokinase-2 MeSH D08.811.913.696.620.240 – galactokinase MeSH D08.811.913.696.620.250 – glucokinase MeSH D08.811.913.696.620.275 – glycerol kinase MeSH D08.811.913.696.620.300 – hexokinase MeSH D08.811.913.696.620.475 – kanamycin kinase MeSH D08.811.913.696.620.525 – 1-phosphatidylinositol 3-kinase MeSH D08.811.913.696.620.550 – 1-phosphatidylinositol 4-kinase MeSH D08.811.913.696.620.650 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.913.696.620.680 – polynucleotide 5'-hydroxyl-kinase MeSH D08.811.913.696.620.682 – protein kinases MeSH D08.811.913.696.620.682.650 – phosphorylase kinase MeSH D08.811.913.696.620.682.700 – protein-serine-threonine kinases MeSH D08.811.913.696.620.682.700.062 – activin receptors MeSH D08.811.913.696.620.682.700.062.500 – activin receptors, type i MeSH D08.811.913.696.620.682.700.062.750 – activin receptors, type ii MeSH D08.811.913.696.620.682.700.109 – bone morphogenetic protein receptors MeSH D08.811.913.696.620.682.700.109.500 – bone morphogenetic protein receptors, type i MeSH D08.811.913.696.620.682.700.109.750 – bone morphogenetic protein receptors, type ii MeSH D08.811.913.696.620.682.700.125 – ca(2+)-calmodulin dependent protein kinase MeSH D08.811.913.696.620.682.700.125.500 – myosin-light-chain kinase MeSH D08.811.913.696.620.682.700.140 – casein kinases MeSH D08.811.913.696.620.682.700.140.300 – casein kinase i MeSH D08.811.913.696.620.682.700.140.300.100 – casein kinase ialpha MeSH D08.811.913.696.620.682.700.140.300.200 – casein kinase idelta MeSH D08.811.913.696.620.682.700.140.300.300 – casein kinase iepsilon MeSH D08.811.913.696.620.682.700.140.600 – casein kinase ii MeSH D08.811.913.696.620.682.700.150 – cyclic nucleotide-regulated protein kinases MeSH D08.811.913.696.620.682.700.150.125 – cyclic amp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.125.500 – beta-adrenergic-receptor kinase MeSH D08.811.913.696.620.682.700.150.150 – cyclic gmp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.575 – protamine kinase MeSH D08.811.913.696.620.682.700.200 – cyclin-dependent kinases MeSH D08.811.913.696.620.682.700.200.067 – cdc2-cdc28 kinases MeSH D08.811.913.696.620.682.700.200.067.249 – cdc2 protein kinase MeSH D08.811.913.696.620.682.700.200.067.500 – cdc28 protein kinase, s cerevisiae MeSH D08.811.913.696.620.682.700.200.067.875 – cyclin-dependent kinase 5 MeSH D08.811.913.696.620.682.700.200.067.900 – cyclin-dependent kinase 9 MeSH D08.811.913.696.620.682.700.200.323 – cyclin-dependent kinase 2 MeSH D08.811.913.696.620.682.700.200.451 – cyclin-dependent kinase 4 MeSH D08.811.913.696.620.682.700.200.515 – cyclin-dependent kinase 6 MeSH D08.811.913.696.620.682.700.200.580 – maturation-promoting factor MeSH D08.811.913.696.620.682.700.200.580.500 – cdc2 protein kinase MeSH D08.811.913.696.620.682.700.250 – dna-activated protein kinase MeSH D08.811.913.696.620.682.700.300 – eif-2 kinase MeSH D08.811.913.696.620.682.700.429 – glycogen synthase kinases MeSH D08.811.913.696.620.682.700.429.500 – glycogen synthase kinase 3 MeSH D08.811.913.696.620.682.700.494 – i-kappa B kinase MeSH D08.811.913.696.620.682.700.559 – map kinase kinase kinases MeSH D08.811.913.696.620.682.700.559.100 – map kinase kinase kinase 1 MeSH D08.811.913.696.620.682.700.559.200 – map kinase kinase kinase 2 MeSH D08.811.913.696.620.682.700.559.300 – map kinase kinase kinase 3 MeSH D08.811.913.696.620.682.700.559.400 – map kinase kinase kinase 4 MeSH D08.811.913.696.620.682.700.559.500 – map kinase kinase kinase 5 MeSH D08.811.913.696.620.682.700.559.800 – proto-oncogene proteins c-mos MeSH D08.811.913.696.620.682.700.559.842 – raf kinases MeSH D08.811.913.696.620.682.700.559.842.249 – oncogene proteins v-raf MeSH D08.811.913.696.620.682.700.559.842.374 – proto-oncogene proteins b-raf MeSH D08.811.913.696.620.682.700.559.842.500 – proto-oncogene proteins c-raf MeSH D08.811.913.696.620.682.700.565 – mitogen-activated protein kinase kinases MeSH D08.811.913.696.620.682.700.565.100 – map kinase kinase 1 MeSH D08.811.913.696.620.682.700.565.200 – map kinase kinase 2 MeSH D08.811.913.696.620.682.700.565.300 – map kinase kinase 3 MeSH D08.811.913.696.620.682.700.565.400 – map kinase kinase 4 MeSH D08.811.913.696.620.682.700.565.500 – map kinase kinase 5 MeSH D08.811.913.696.620.682.700.565.600 – map kinase kinase 6 MeSH D08.811.913.696.620.682.700.565.700 – map kinase kinase 7 MeSH D08.811.913.696.620.682.700.567 – mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.567.342 – extracellular signal-regulated map kinases MeSH D08.811.913.696.620.682.700.567.342.500 – mitogen-activated protein kinase 1 MeSH D08.811.913.696.620.682.700.567.342.750 – mitogen-activated protein kinase 3 MeSH D08.811.913.696.620.682.700.567.342.875 – mitogen-activated protein kinase 6 MeSH D08.811.913.696.620.682.700.567.342.937 – mitogen-activated protein kinase 7 MeSH D08.811.913.696.620.682.700.567.513 – jnk mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.567.513.500 – mitogen-activated protein kinase 8 MeSH D08.811.913.696.620.682.700.567.513.750 – mitogen-activated protein kinase 9 MeSH D08.811.913.696.620.682.700.567.513.800 – mitogen-activated protein kinase 10 MeSH D08.811.913.696.620.682.700.567.878 – p38 mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.586 – oncogene protein v-akt MeSH D08.811.913.696.620.682.700.606 – phytochrome a MeSH D08.811.913.696.620.682.700.646 – proline-directed protein kinases MeSH D08.811.913.696.620.682.700.646.500 – cyclin-dependent kinases MeSH D08.811.913.696.620.682.700.646.500.500 – cdc2-cdc28 kinases MeSH D08.811.913.696.620.682.700.646.500.500.500 – cyclin-dependent kinase 5 MeSH D08.811.913.696.620.682.700.646.500.750 – cyclin-dependent kinase 2 MeSH D08.811.913.696.620.682.700.646.500.875 – cyclin-dependent kinase 4 MeSH D08.811.913.696.620.682.700.646.500.937 – cyclin-dependent kinase 6 MeSH D08.811.913.696.620.682.700.646.625 – glycogen synthase kinase 3 MeSH D08.811.913.696.620.682.700.646.750 – mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.646.750.249 – extracellular signal-regulated map kinases MeSH D08.811.913.696.620.682.700.646.750.249.500 – mitogen-activated protein kinase 1 MeSH D08.811.913.696.620.682.700.646.750.249.750 – mitogen-activated protein kinase 3 MeSH D08.811.913.696.620.682.700.646.750.249.875 – mitogen-activated protein kinase 6 MeSH D08.811.913.696.620.682.700.646.750.249.937 – mitogen-activated protein kinase 7 MeSH D08.811.913.696.620.682.700.646.750.374 – jnk mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.646.750.374.500 – mitogen-activated protein kinase 8 MeSH D08.811.913.696.620.682.700.646.750.374.750 – mitogen-activated protein kinase 9 MeSH D08.811.913.696.620.682.700.646.750.374.800 – mitogen-activated protein kinase 10 MeSH D08.811.913.696.620.682.700.646.750.843 – p38 mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.725 – protein kinase C MeSH D08.811.913.696.620.682.700.725.100 – protein kinase C-alpha MeSH D08.811.913.696.620.682.700.725.400 – protein kinase C-delta MeSH D08.811.913.696.620.682.700.725.750 – protein kinase C-epsilon MeSH D08.811.913.696.620.682.700.755 – proto-oncogene proteins C-akt MeSH D08.811.913.696.620.682.700.759 – proto-oncogene proteins C-bcr MeSH D08.811.913.696.620.682.700.776 – proto-oncogene proteins C-pim-1 MeSH D08.811.913.696.620.682.700.827 – rhodopsin kinase MeSH D08.811.913.696.620.682.700.862 – ribosomal protein s6 kinases MeSH D08.811.913.696.620.682.700.862.249 – ribosomal protein s6 kinases, 70-kda MeSH D08.811.913.696.620.682.700.862.500 – ribosomal protein s6 kinases, 90-kda MeSH D08.811.913.696.620.682.725 – protein-tyrosine kinase MeSH D08.811.913.696.620.682.725.049 – focal adhesion protein-tyrosine kinases MeSH D08.811.913.696.620.682.725.049.500 – focal adhesion kinase 1 MeSH D08.811.913.696.620.682.725.049.750 – focal adhesion kinase 2 MeSH D08.811.913.696.620.682.725.200 – mitogen-activated protein kinase kinases MeSH D08.811.913.696.620.682.725.200.100 – map kinase kinase 1 MeSH D08.811.913.696.620.682.725.200.200 – map kinase kinase 2 MeSH D08.811.913.696.620.682.725.200.300 – map kinase kinase 3 MeSH D08.811.913.696.620.682.725.200.400 – map kinase kinase 4 MeSH D08.811.913.696.620.682.725.200.500 – map kinase kinase 5 MeSH D08.811.913.696.620.682.725.200.600 – map kinase kinase 6 MeSH D08.811.913.696.620.682.725.200.700 – map kinase kinase 7 MeSH D08.811.913.696.620.682.725.300 – proto-oncogene proteins c-fes MeSH D08.811.913.696.620.682.725.400 – receptor protein-tyrosine kinases MeSH D08.811.913.696.620.682.725.400.020 – fms-like tyrosine kinase 3 MeSH D08.811.913.696.620.682.725.400.024 – receptor, fibroblast growth factor, type 1 MeSH D08.811.913.696.620.682.725.400.037 – receptor, fibroblast growth factor, type 2 MeSH D08.811.913.696.620.682.725.400.043 – receptor, fibroblast growth factor, type 3 MeSH D08.811.913.696.620.682.725.400.046 – receptor, fibroblast growth factor, type 4 MeSH D08.811.913.696.620.682.725.400.050 – proto-oncogene proteins c-kit MeSH D08.811.913.696.620.682.725.400.075 – proto-oncogene proteins c-met MeSH D08.811.913.696.620.682.725.400.087 – proto-oncogene proteins c-ret MeSH D08.811.913.696.620.682.725.400.100 – receptor, epidermal growth factor MeSH D08.811.913.696.620.682.725.400.150 – receptor, erbb-2 MeSH D08.811.913.696.620.682.725.400.175 – receptor, erbb-3 MeSH D08.811.913.696.620.682.725.400.185 – receptor, igf type 1 MeSH D08.811.913.696.620.682.725.400.200 – receptor, insulin MeSH D08.811.913.696.620.682.725.400.500 – receptor, macrophage colony-stimulating factor MeSH D08.811.913.696.620.682.725.400.660 – receptor, trka MeSH D08.811.913.696.620.682.725.400.700 – receptor, trkb MeSH D08.811.913.696.620.682.725.400.800 – receptor, trkc MeSH D08.811.913.696.620.682.725.400.850 – receptors, eph family MeSH D08.811.913.696.620.682.725.400.850.050 – receptor, epha1 MeSH D08.811.913.696.620.682.725.400.850.100 – receptor, epha2 MeSH D08.811.913.696.620.682.725.400.850.150 – receptor, epha3 MeSH D08.811.913.696.620.682.725.400.850.200 – receptor, epha4 MeSH D08.811.913.696.620.682.725.400.850.250 – receptor, epha5 MeSH D08.811.913.696.620.682.725.400.850.300 – receptor, epha6 MeSH D08.811.913.696.620.682.725.400.850.400 – receptor, epha7 MeSH D08.811.913.696.620.682.725.400.850.500 – receptor, epha8 MeSH D08.811.913.696.620.682.725.400.850.600 – receptor, ephb1 MeSH D08.811.913.696.620.682.725.400.850.650 – receptor, ephb2 MeSH D08.811.913.696.620.682.725.400.850.700 – receptor, ephb3 MeSH D08.811.913.696.620.682.725.400.850.750 – receptor, ephb4 MeSH D08.811.913.696.620.682.725.400.850.800 – receptor, ephb5 MeSH D08.811.913.696.620.682.725.400.900 – receptors, platelet-derived growth factor MeSH D08.811.913.696.620.682.725.400.900.500 – receptor, platelet-derived growth factor alpha MeSH D08.811.913.696.620.682.725.400.900.750 – receptor, platelet-derived growth factor beta MeSH D08.811.913.696.620.682.725.400.925 – receptors, tie MeSH D08.811.913.696.620.682.725.400.925.249 – receptor, tie-1 MeSH D08.811.913.696.620.682.725.400.925.500 – receptor, tie-2 MeSH D08.811.913.696.620.682.725.400.950 – receptors, vascular endothelial growth factor MeSH D08.811.913.696.620.682.725.400.950.100 – vascular endothelial growth factor receptor-1 MeSH D08.811.913.696.620.682.725.400.950.200 – vascular endothelial growth factor receptor 2 MeSH D08.811.913.696.620.682.725.400.950.300 – vascular endothelial growth factor receptor-3 MeSH D08.811.913.696.620.682.725.500 – proto-oncogene proteins c-abl MeSH D08.811.913.696.620.682.725.800 – src-family kinases MeSH D08.811.913.696.620.682.725.800.315 – lymphocyte specific protein tyrosine kinase p56(lck) MeSH D08.811.913.696.620.682.725.800.472 – oncogene protein pp60(v-src) MeSH D08.811.913.696.620.682.725.800.551 – proto-oncogene proteins c-fyn MeSH D08.811.913.696.620.682.725.800.590 – proto-oncogene proteins c-hck MeSH D08.811.913.696.620.682.725.800.610 – proto-oncogene proteins c-yes MeSH D08.811.913.696.620.682.725.800.630 – proto-oncogene proteins pp60(c-src) MeSH D08.811.913.696.620.682.725.900 – zap-70 protein-tyrosine kinase MeSH D08.811.913.696.620.685 – pyridoxal kinase MeSH D08.811.913.696.620.695 – pyruvate kinase MeSH D08.811.913.696.620.750 – thymidine kinase MeSH D08.811.913.696.620.800 – uridine kinase MeSH D08.811.913.696.630 – phosphotransferases (carboxyl group acceptor) MeSH D08.811.913.696.630.025 – acetate kinase MeSH D08.811.913.696.630.050 – aspartate kinase MeSH D08.811.913.696.630.050.050 – aspartokinase homoserine dehydrogenase MeSH D08.811.913.696.630.700 – phosphoglycerate kinase MeSH D08.811.913.696.640 – phosphotransferases (nitrogenous group acceptor) MeSH D08.811.913.696.640.025 – arginine kinase MeSH D08.811.913.696.640.150 – creatine kinase MeSH D08.811.913.696.640.150.500 – creatine kinase, bb form MeSH D08.811.913.696.640.150.625 – creatine kinase, mb form MeSH D08.811.913.696.640.150.750 – creatine kinase, mitochondrial form MeSH D08.811.913.696.640.150.875 – creatine kinase, mm form MeSH D08.811.913.696.645 – phosphotransferases (paired acceptors) MeSH D08.811.913.696.645.700 – pyruvate, orthophosphate dikinase MeSH D08.811.913.696.650 – phosphotransferases (phosphate group acceptor) MeSH D08.811.913.696.650.025 – adenylate kinase MeSH D08.811.913.696.650.150 – atp synthetase complexes MeSH D08.811.913.696.650.150.500 – proton-translocating atpases MeSH D08.811.913.696.650.150.500.249 – bacterial proton-translocating atpases MeSH D08.811.913.696.650.150.500.500 – chloroplast proton-translocating atpases MeSH D08.811.913.696.650.150.500.750 – mitochondrial proton-translocating atpases MeSH D08.811.913.696.650.150.500.875 – vacuolar proton-translocating atpases MeSH D08.811.913.696.650.450 – guanylate kinase MeSH D08.811.913.696.650.550 – nucleoside-diphosphate kinase MeSH D08.811.913.696.650.575 – nucleoside-phosphate kinase MeSH D08.811.913.696.900 – transferases (other substituted phosphate groups) MeSH D08.811.913.696.900.074 – CDP-diacylglycerol—inositol 3-phosphatidyltransferase MeSH D08.811.913.696.900.150 – CDP-diacylglycerol—serine O-phosphatidyltransferase MeSH D08.811.913.696.900.200 – diacylglycerol cholinephosphotransferase MeSH D08.811.913.696.900.250 – ethanolaminephosphotransferase
Because of this fact, it has become common practice to establish the quality of NMR ensembles, by comparing it against the unique conformation determined by X-ray diffraction, for the same protein. However, the X-ray diffraction structure may not exist, and, since the proteins in solution are flexible molecules, a protein represented by a single structure may lead to underestimate the intrinsic variation of the atomic positions of a protein. A set of conformations, determined by NMR or X-ray crystallography may be a better representation of the experimental data of a protein than a unique conformation. The utility of a model will be given, at least in part, by the degree of accuracy and precision of the model. An accurate model with relatively poor precision could be useful to study the evolutionary relationships between the structures of a set of proteins, whereas the rational drug design requires both precise and accurate models. A model that is not accurate, regardless of the degree of precision with which it was obtained will not be very useful. Since protein structures are experimental models that can contain errors, it is very important to be able to detect these errors. The process aimed at the detection of errors is known as validation. There are several methods to validate structures, some are statistical like PROCHECK and WHAT IF while others are based on physical principles as CheShift, or a mixture of statistical and physics principles PSVS.
The low energy consumption, low maintenance and small size of LEDs has led to uses as status indicators and displays on a variety of equipment and installations. Large-area LED displays are used as stadium displays, dynamic decorative displays, and dynamic message signs on freeways. Thin, lightweight message displays are used at airports and railway stations, and as destination displays for trains, buses, trams, and ferries.
Sources: en.wikipedia.org
==== Use as an inhaled agitation medication ==== Loxapine has a relatively strong safety profile compared to similar antipsychotic drugs, such as quetiapine, olanzapine, and clozapine, with a relatively lower incidence of metabolic side-effects (although higher extrapyramial side-effects). Given its strong safety profile and speed/efficacy when given intramuscularly for acute agitation, an inhaled version of the drug (Adasuve) has been developed to be applied nasally for agitated patients needing to be rapidly de-escalated.
More than 80% of newborns develop jaundice within several days of birth. Jaundice, or yellowing of the skin and eyes, occurs when bilirubin, a byproduct of the breakdown/recycling of red blood cells, builds up in the newborn's bloodstream faster than the liver can break it down and excrete it through the baby's urine and stool. By continuing to breastfeed frequently (start at 8-12 times per day), the infant's body can usually rid itself of the bilirubin excess by encouraging more urine and stool production. However, in some cases, the infant may need additional treatments, such as UV light therapy or additional feedings (see Supplementation) to keep the condition from progressing into more severe problems. There are two types of newborn jaundice related to breastfeeding. Breastfeeding jaundice is quite common and may occur in the first week of life in conjunction with ongoing weight loss. The cause is thought to be low caloric intake. Formula-fed infants tend to lose less weight after birth compared to breastfed infants, supporting the hypothesis that breastfeeding jaundice is related to caloric intake rather than volume intake. Individual risk factors, such as breastfeeding, are not predictive of developing severe jaundice: Breastfeeding is a risk factor for severely high levels of bilirubin, but the risk factor is very common, and the risk of severely high bilirubin remains small. Breast milk jaundice is jaundice that persists despite appropriate weight gain.
Although this model is recommended by the National Institute of Mental Health (NIMH), critics claim that it has the potential to create power struggles in an intimate relationship and may disrupt equal partnerships.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.